热搜词：
注册
登录
CN
  • CN
  • EN

产品中心 ELISA试剂盒 OneStep ELISA 试剂盒

所有图片（1/6）

Human VEGFA OneStep ELISA Kit

价格 ￥4,800.00 （ 供应商现货 ： 3-5个工作日）
货号 S0C3124
规格
数量
收藏 分享
产品介绍

产品介绍 评论(0)

产品规格

  • 抗原名称

    VEGFA

  • 免疫原

    Recombinant Protein

  • 抗体类型

    Recombinant mAb

  • 反应种属 ?

    Hu

  • 纯化方式

    Protein A

  • 储存条件

    12 months from date of receipt / reconstitution, 2 to 8'C as supplied.

试剂盒参数

    • Precision

      Intra-assay: 2.7%；
      Inter-assay: 5.4%

    • Sample type

      Serum; Plasma; Cell culture supernatant

    • Assay type

      Sandwich (quantitative)

    • Sensitivity

      17.123 pg/mL

    • Range

      78.13 pg/mL – 5000 pg/mL

    • Recovery

      Serum: 104%
      Plasma: 80%
      Cell culture supernatant: 92%

    • Assay time

      60 minutes

    • Species reactivity

      Hu
背景介绍

  • Vascular endothelial growth factor (VEGF) is a subfamily of growth factors that play a critical role in stimulating angiogenesis—the formation of new blood vessels. As a key signaling protein, VEGF is involved in both embryonic vascular development and the physiological or pathological growth of existing vasculature. The VEGF family comprises several members, including VEGF-A, VEGF-B, VEGF-C, VEGF-D, and placental growth factor (PlGF), with VEGF-A being the first identified. Prior to the discovery of other isoforms, VEGF-A was commonly referred to as VEGF. Due to its central role in promoting tumor angiogenesis, VEGF is essential for tumor development and metastasis, making it a pivotal target in cancer therapeutics. Accumulating evidence indicates that single nucleotide polymorphisms (SNPs) within the VEGF gene may serve as predictive and prognostic biomarkers for major solid tumors, such as breast cancer, non-small cell lung cancer, colorectal cancer, and prostate cancer.

  • ELISA

    • Standard curve
      Example of Human VEGFA standard curve in Assay Diluent #11.

    • Linearity
      The concentrations of Human VEGFA were measured and interpolated from the target standard curves and corrected for sample dilution.
      #1 sample is undiluted samples are as follows: human plasma-Heparin (100%). The interpolated dilution factor corrected values are plotted. The mean target concentration was determined to be 141.18 pg/mL in human plasma-Heparin.
      #2 sample is undiluted samples are as follows: human plasma-Citrate (100%). The interpolated dilution factor corrected values are plotted. The mean target concentration was determined to be 243.03 pg/mL in human plasma-Citrate.
      #3 sample is undiluted samples are as follows: A549 supernatant (100%). The interpolated dilution factor corrected values are plotted. The mean target concentration was determined to be 162.55 pg/mL in A549 supernatant.

    • The sample is undiluted samples are as follows: A431 supernatant (50%). The interpolated dilution factor corrected values are plotted. The mean target concentration was determined to be 5888.62 pg/mL in A431 supernatant.

    • To assess the linearity of the assay, two samples were spiked with high concentrations of Human VEGFA in various matrices and diluted with the appropriate Calibrator Diluent to produce samples with values within the dynamic range of the assay.

    • To assess the linearity of the assay, the sample was spiked with high concentrations of Human VEGFA in various matrices and diluted with the appropriate Calibrator Diluent to produce samples with values within the dynamic range of the assay.

    • Protocol Diagram

评论(0)